biostudies-literatureUnknown8(12)Loap P<h4>Importance</h4>Triple-negative breast cancer (TNBC) cells are sensitive to poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors used as radiosensitizers. Whether combining PARP inhibitors with radiotherapy in patients with TNBC would enhance the biological effectiveness of the irradiation and improve locoregional control is unclear.<h4>Objective</h4>To assess the safety and tolerability of PARP inhibition with olaparib used concurrently with radiotherapy in patients with TNBC with residual disease after neoadjuvant chemotherapy.<h4>Design, setting, and participants</h4>This phase 1 prospective dose-escalation trial (Olaparib and Radiation Therapy for TNBC [RadioPARP] trial) using a time-to-event continual reassessment method was performed from September 2017 to November 2019JAMA oncology1802-1808https://www.ebi.ac.uk/biostudies/studies/S-EPMC9614672biostudies-literatureConcurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.PMC9614672Laki FBoudali LDiallo MRodrigues MEeckhoutte ARaizonville LLoirat DBerger FVincent-Salomon AJochem AMosseri VLoap PBazire LPierga JYStern MHKirova YFourquet AfalseConcurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.<h4>Importance</h4>Triple-negative breast cancer (TNBC) cells are sensitive to poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors used as radiosensitizers. Whether combining PARP inhibitors with radiotherapy in patients with TNBC would enhance the biological effectiveness of the irradiation and improve locoregional control is unclear.<h4>Objective</h4>To assess the safety and tolerability of PARP inhibition with olaparib used concurrently with radiotherapy in patients with TNBC with residual disease after neoadjuvant chemotherapy.<h4>Design, setting, and participants</h4>This phase 1 prospective dose-escalation trial (Olaparib and Radiation Therapy for TNBC [RadioPARP] trial) using a time-to-event continual reassessment method was performed from September 2017 to November 20192022-01-01T00:00:00Z2022 Dec2026-05-28T02:03:27.684Z2025-04-07T01:56:55.239ZS-EPMC96146723630157210.1001/jamaoncol.2022.5074